Dual-Intent Clinical Evidence: How to Plan One Study for FDA Clearance and Medicare Coverage

Dual-intent clinical evidence is a single evidence plan designed to answer two different questions: whether FDA can authorize the device for marketing, and whether Medicare and other payers will cover and pay for it. FDA asks about safety and effectiveness, or substantial equivalence. Medicare asks whether the item is reasonable and necessary for its beneficiaries. One study can serve both only if the team plans for both before the protocol is locked.

Our October 2026 MedTech Pulse reported that CMS repealed the alternative pathway that let FDA Breakthrough Devices qualify for supplemental hospital payments without separately showing substantial clinical improvement. That makes payer-ready evidence a design decision, not a post-clearance task. This guide explains how to plan it, using the free Cahir MedTech Dual-Intent Clinical Evidence Planning Worksheet.

Why FDA clearance does not guarantee coverage or payment

FDA authorization and Medicare coverage are separate decisions made by separate agencies under separate laws. FDA decides whether a device may be marketed. Under section 1862(a)(1)(A) of the Social Security Act, Medicare generally pays only for items and services that are reasonable and necessary for diagnosis or treatment. Coding and payment are further separate steps.

A study that is sufficient for FDA can still leave coverage and payment gaps. Common examples are a technical-performance primary endpoint, a population that excludes older patients, or no comparison with the treatment patients actually receive today.

Start with the FDA pathway and study type

Confirm the expected pathway first: 510(k), De Novo or PMA. Then decide whether the clinical study is significant risk. A significant-risk device study needs an approved investigational device exemption, or IDE, under 21 CFR Part 812 before it begins. FDA's IDE program page explains approval and reporting requirements.

FDA's guidance on design considerations for pivotal clinical investigations covers study design, endpoints, controls and bias. Use a Q-Submission to get FDA feedback on the protocol. For pathway background, see our FDA premarket pathways guide.

Name the payer question before choosing endpoints

Write down which coverage and payment routes you expect to pursue. Each route shapes the evidence you need:

• **National or local coverage.** Search the Medicare Coverage Database for existing national and local coverage determinations in your clinical area.
• **Coverage with evidence development.** CMS can cover an item while requiring further data collection under coverage with evidence development.
• **TCET.** Under the Transitional Coverage for Emerging Technologies final notice, CMS anticipates accepting up to five FDA-designated Breakthrough Devices per year, with a goal of finalizing a national coverage determination within six months after FDA market authorization.
• **Supplemental hospital payment.** Inpatient new technology add-on payments and outpatient device pass-through payments have their own eligibility criteria, including substantial clinical improvement.
• **Coding.** Check whether existing codes describe the service or whether a new HCPCS or CPT code is needed.

A Breakthrough designation can make a device eligible for some of these routes, but it does not by itself establish coverage or supplemental payment.

Map every endpoint to FDA, payers or both

The core of a dual-intent plan is an endpoint map. List each primary, secondary and safety endpoint and mark whether it supports FDA, payers or both.

The worksheet's Endpoint Map flags every endpoint marked FDA only, so the team decides deliberately whether payers need more. Adding a secondary endpoint or follow-up visit during design is far cheaper than a second study after clearance.

Choose comparators and populations payers recognize

Payers compare a new device with current care. Record the standard-of-care comparator, and check that the enrolled population reflects the people who will use the device, including Medicare-age patients where relevant. Collect resource-use data, such as procedure time, length of stay, readmissions and reinterventions, while the study runs. Retrofitting these data later is slow and often incomplete.

Where a randomized comparison is not feasible, plan how real-world evidence or registry data could supplement the pivotal study. For health-economic modeling, see our guide to budget impact models and the medical device market-access guide.

Build one integrated timeline

Place FDA and payer milestones in one schedule: Pre-Submission feedback, IDE approval, first enrollment, primary readout, FDA submission and decision, coding application, coverage request or TCET nomination, and NTAP or pass-through application. Coverage and payment applications have their own submission windows, so confirm current CMS dates for each cycle rather than copying them from a prior year.

How to use the free worksheet

The Dual-Intent Clinical Evidence Planning Worksheet is a branded Excel file with six tabs: Start Here, Endpoint Map, Pathway and Payer Plan, Comparator and Economics, Timeline, and Sources and Applicability. Download it free with a work email from the toolkits page. Use it to align clinical, regulatory and market-access owners before the protocol is finalized, then track the plan in your company workspace.

For help drafting protocols, evidence summaries and submission documents, explore Cahir MedTech Copilot. To compare reimbursement routes across markets, use MedTech Compass. Keep qualified clinical, regulatory and reimbursement review in the process.

Dual-intent clinical evidence: quick answers

What is dual-intent clinical evidence?

Dual-intent clinical evidence is a study and data plan designed to support both FDA marketing authorization and payer coverage and payment. It deliberately includes endpoints, comparators and populations that payers need, not only those FDA needs.

Does FDA clearance mean Medicare will cover my device?

No. FDA authorization and Medicare coverage are separate decisions. Medicare generally covers items that are reasonable and necessary for its beneficiaries, and coding and payment are further separate steps.

Does Breakthrough designation guarantee Medicare payment?

No. Breakthrough designation can make a device eligible for routes such as TCET, but it does not by itself establish coverage. CMS has also repealed the alternative pathway that let Breakthrough Devices qualify for supplemental payments without showing substantial clinical improvement.

What is TCET?

TCET, Transitional Coverage for Emerging Technologies, is a CMS coverage pathway for certain FDA-designated Breakthrough Devices. CMS anticipates accepting up to five candidates per year and aims to finalize a national coverage determination within six months after FDA market authorization.

When should payer evidence be planned?

Before the pivotal protocol is locked. Adding endpoints, follow-up visits or resource-use data during design costs far less than running another study after clearance.

Is the Cahir MedTech worksheet an FDA or CMS form?

No. It is a free, work-email-gated Excel planning aid. It does not replace FDA or CMS submissions, legal advice or qualified regulatory and reimbursement review.

Sources and applicability

• 21 CFR Part 812: investigational device exemptions.
• FDA pivotal clinical investigations guidance: study design considerations.
• FDA Q-Submission guidance: feedback on study design.
• FDA Breakthrough Devices Program.
• CMS TCET final notice.
• CMS coverage with evidence development.
• CMS new technology add-on payments and device pass-through payments.
• CMS FY 2027 inpatient payment final rule fact sheet.
• Medicare Coverage Database.

Published October 28, 2026. Sources checked for this edition; confirm current FDA and CMS requirements for your device. This article and worksheet are educational planning tools, not legal, regulatory or reimbursement advice.